image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.0
1.01 %
$ 37.8 M
Market Cap
-1.52
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one APYX stock under the worst case scenario is HIDDEN Compared to the current market price of 1 USD, Apyx Medical Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one APYX stock under the base case scenario is HIDDEN Compared to the current market price of 1 USD, Apyx Medical Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one APYX stock under the best case scenario is HIDDEN Compared to the current market price of 1 USD, Apyx Medical Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart APYX

image
$1.9$1.9$1.8$1.8$1.7$1.7$1.6$1.6$1.5$1.5$1.4$1.4$1.3$1.3$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.915 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
48.1 M REVENUE
-8.11%
-18.8 M OPERATING INCOME
-9.19%
-23.6 M NET INCOME
-24.98%
-18 M OPERATING CASH FLOW
-243.82%
-722 K INVESTING CASH FLOW
-10.72%
6.74 M FINANCING CASH FLOW
-79.03%
14.2 M REVENUE
23.81%
-3.05 M OPERATING INCOME
16.15%
-4.66 M NET INCOME
2.29%
-2.94 M OPERATING CASH FLOW
33.85%
-245 K INVESTING CASH FLOW
-60.13%
6.76 M FINANCING CASH FLOW
135300.00%
Balance Sheet Apyx Medical Corporation
image
Current Assets 56.4 M
Cash & Short-Term Investments 31.7 M
Receivables 15.5 M
Other Current Assets 9.22 M
Non-Current Assets 8.4 M
Long-Term Investments 0
PP&E 6.74 M
Other Non-Current Assets 1.66 M
48.95 %23.87 %14.22 %10.39 %Total Assets$64.8m
Current Liabilities 10.7 M
Accounts Payable 2.62 M
Short-Term Debt 355 K
Other Current Liabilities 7.75 M
Non-Current Liabilities 39.8 M
Long-Term Debt 4.52 M
Other Non-Current Liabilities 35.3 M
5.18 %15.35 %8.94 %69.83 %Total Liabilities$50.5m
EFFICIENCY
Earnings Waterfall Apyx Medical Corporation
image
Revenue 48.1 M
Cost Of Revenue 18.7 M
Gross Profit 29.4 M
Operating Expenses 48.2 M
Operating Income -18.8 M
Other Expenses 4.71 M
Net Income -23.6 M
50m50m40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)48m(19m)29m(48m)(19m)(5m)(24m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
61.04% GROSS MARGIN
61.04%
-39.18% OPERATING MARGIN
-39.18%
-48.78% NET MARGIN
-48.78%
-165.12% ROE
-165.12%
-36.18% ROA
-36.18%
-34.97% ROIC
-34.97%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Apyx Medical Corporation
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -23.6 M
Depreciation & Amortization 599 K
Capital Expenditures -722 K
Stock-Based Compensation 4.01 M
Change in Working Capital 0
Others 900 K
Free Cash Flow -18.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Apyx Medical Corporation
image
Wall Street analysts predict an average 1-year price target for APYX of $11.3 , with forecasts ranging from a low of $5 to a high of $17 .
APYX Lowest Price Target Wall Street Target
5 USD 400.00%
APYX Average Price Target Wall Street Target
11.3 USD 1033.33%
APYX Highest Price Target Wall Street Target
17 USD 1600.00%
Price
Max Price Target
Min Price Target
Average Price Target
181816161414121210108866442200May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Apyx Medical Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
12.8 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Renuvion wins 2025 NewBeauty Award for "Best Minimally Invasive Skin Tightener" Renuvion is the first and only body contouring technology that empowers consumers to feel and look their best, from the inside out by treating loose skin CLEARWATER, Fla. , March 25, 2025 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ: APYX) ("Apyx Medical" or the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, announced today that Renuvion has been named this year's NewBeauty Award winner in the "Best Minimally Invasive Skin Tightener"1 category. prnewswire.com - 3 weeks ago
Apyx Medical Corporation (APYX) Q4 2024 Earnings Call Transcript Apyx Medical Corporation (NASDAQ:APYX ) Q4 2024 Earnings Conference Call March 13, 2025 8:30 AM ET Company Participants Jeremy Feffer - MD, LifeSci Advisors Charlie Goodwin - CEO Matt Hill - CFO Conference Call Participants Matthew O'Brien - Piper Sandler Matt Hewitt - Craig-Hallum Capital Group Sam Eiber - BTIG Operator Greetings. Welcome to the Apyx Medical Fourth Quarter and Full Year 2024 Conference Call. seekingalpha.com - 1 month ago
Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates Apyx Medical (APYX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.19 per share a year ago. zacks.com - 1 month ago
Apyx Medical Corporation Submits 510(k) Premarket Notification to the U.S. Food and Drug Administration for the AYON Body Contouring System™ Focusing on advancing body contouring by providing the first all-in-one platform for the surgical suite Focusing on advancing body contouring by providing the first all-in-one platform for the surgical suite globenewswire.com - 3 months ago
Apyx Medical Corporation to Attend 15th Annual Craig-Hallum Alpha Select Conference CLEARWATER, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that Charles Goodwin, President and CEO and Matt Hill, CFO will be attending the following upcoming conference: globenewswire.com - 5 months ago
Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript Apyx Medical Corporation (NASDAQ:APYX ) Q3 2024 Earnings Call Transcript November 8, 2024 8:00 AM ET Company Participants Jeremy Feffer - MD, LifeSci Advisors Stavros Vizirgianakis - Executive Chairman Charlie Goodwin - CEO Matt Hill - CFO Conference Call Participants Matthew O'Brien - Piper Sandler Matt Hewitt - Craig-Hallum Capital Group Sam Eiber - BTIG Ben Haynor - Lake Street Capital Markets Operator Ladies and gentlemen, good morning, and welcome to the Apyx Medical Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 5 months ago
Apyx Medical (APYX) Reports Q3 Loss, Lags Revenue Estimates Apyx Medical (APYX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.13 per share a year ago. zacks.com - 5 months ago
Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced it has entered into a definitive purchase agreement with Nantahala Capital for the purchase and sale in a registered direct offering of 3,000,000 shares of the Company's common stock at a purchase price of $1.18 per share and pre-funded warrants to purchase up to 2,934,690 shares of the Company's common stock at a purchase price of $1.179 per pre-funded warrant (which represents the per share offering price for common stock less the exercise price per share for each pre-funded warrant of $0.001). The gross proceeds to Apyx Medical from the offering were approximately $7,000,000, before deducting offering expenses payable by the Company. The offering closed on November 8, 2024. globenewswire.com - 5 months ago
Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its third quarter ended September 30, 2024, updated its financial expectations for the full year ending December 31, 2024, and introduced its financial expectations for the full year ending December 31, 2025. globenewswire.com - 5 months ago
Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024 CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th. globenewswire.com - 5 months ago
Apyx (APYX) Upgraded to Buy: Here's What You Should Know Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 6 months ago
Renuvion Named #1 Trusted Body Contouring Technology by Doctors* Independent survey reveals Renuvion is #1 trusted body contouring technology* with plastic and cosmetic surgeons. CLEARWATER, Fla. prnewswire.com - 8 months ago
8. Profile Summary

Apyx Medical Corporation APYX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 37.8 M
Dividend Yield 0.00%
Description Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Contact 5115 Ulmerton Road, Clearwater, FL, 33760 https://www.apyxmedical.com
IPO Date Jan. 2, 2019
Employees 220
Officers Mr. Matthew C. Hill CPA Chief Financial Officer, Treasurer & Secretary Mr. Stavros George Vizirgianakis B.Com. Executive Chairman Mr. Shawn D. Roman Chief Operating Officer Mr. Charles D. Goodwin II President, Chief Executive Officer & Director Mr. Moshe Citronowicz Senior Vice President